Kidswell Bio Corporation [4584.T]
TOKYO, May 14 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) revised its fiscal year 2026 earnings forecast due to unforeseen expenses and revenues exceeding initial expectations. For the fiscal year ending March 31, 2026, the company reported revenue of ¥6.589 billion compared to the previous estimate of ¥6 billion.
Operating profit was lower than expected at ¥--¥138 million against the earlier projection of ¥-¥100 million. Net income per share decreased to ¥--¥8.5 million from the previously anticipated value. The discrepancy stems primarily from higher-than-projected sales driven by advanced deliveries of certain products during the fiscal year. However, unexpected asset impairment losses associated with some inventory items led to reduced operating margins.
Additionally, interest payments totaling ¥47.6 million were recorded as extraordinary expenses, while compensation received from partner pharmaceutical companies amounted to ¥35 million. Furthermore, the company recognized investment securities valuation losses of ¥15.8 million and lease termination costs of ¥21.8 million related to research facility consolidation efforts. These factors collectively impacted the overall profitability below the projected range. Despite these challenges, Kidswell expects to achieve its planned consolidated operating profit for the next fiscal year through cost reduction measures and price adjustments.
🟢 Confidence: High AI-translated content.